Changes in total cholesterol levels in Western societies are not related to statin, but rather dietary factors: The example of the Icelandic population

European Heart Journal

Volumn 34, Issue 24, 2013, Pages 1778-1782

  Thorsson, Bolli ^a   Steingrimsdottir, Laufey ^b   Halldorsdottir, Sigrun ^a   Andersen, Karl ^b,c   Sigurdsson, Gunnar ^b,c   Aspelund, Thor ^a,b   Gudnason, Vilmundur ^a,b  

^a ICELANDIC HEART ASSOCIATION   (Iceland)

^b UNIVERSITY OF ICELAND   (Iceland)

^c LANDSPITALI UNIVERSITY HOSPITAL   (Iceland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

CHOLESTEROL BLOOD LEVEL; DIET; HUMAN; ICELAND; NOTE; POPULATION RESEARCH; PRIORITY JOURNAL; TREND STUDY; UNITED KINGDOM;

ADULT; AGED; AGED, 80 AND OVER; CHOLESTEROL; CORONARY DISEASE; DIET; EUROPE; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; ICELAND; MALE; MIDDLE AGED;

EID: 84879527542     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs395     Document Type: Note

References (20)

1. Farzadfar F, Finucane MM, Danaei G, Pelizzari PM, Cowan MJ, Paciorek CJ, Singh GM, Lin JK, Stevens GA, Riley LM, Ezzati M. National, regional, and global trends in serum total cholesterol since 1980: systematic analysis of health examination surveys and epidemiological studies with 321 country-years and 3.0 million participants. Lancet 2011;377:578-586.
2. Arnett DK, Jacobs DR Jr, Luepker RV, Blackburn H, Armstrong C, Claas SA. Twenty-year trends in serum cholesterol, hypercholesterolemia, and cholesterol medication use: the Minnesota Heart Survey, 1980-1982 to 2000-2002. Circulation 2005;112:3884-3891.
3. Eliasson M, Janlert U, Jansson JH, Stegmayr B. Time trends in population cholesterol levels 1986-2004: influence of lipid-lowering drugs, obesity, smoking and educational level. The northern Sweden MONICA study. J Intern Med 2006; 260:551-559.
4. Valsta LM, Tapanainen H, Sundvall J, Laatikainen T, Mannisto S, Pietinen P, Vartiainen E. Explaining the 25-year decline of serum cholesterol by dietary changes and use of lipid-lowering medication in Finland. Public Health Nutr 2010;13:932-938.
5. Cifkova R, Skodova Z, Bruthans J, Adamkova V, Jozifova M, Galovcova M, Wohlfahrt P, Krajcoviechova A, Poledne R, Stavek P, Lanska V. Longitudinal trends in major cardiovascular risk factors in the Czech population between 1985 and 2007/8. Czech MONICA and Czech post-MONICA. Atherosclerosis 2010;211:676-681.
6. Capewell S, Beaglehole R, Seddon M, McMurray J. Explanation for the decline in coronary heart disease mortality rates in Auckland, New Zealand, Between 1982 and 1993. Circulation 2000;102:1511-1516.
7. Unal B, Critchley JA, Capewell S. Explaining the decline in coronary heart disease mortality in England and Wales Between 1981 and 2000. Circulation 2004;109: 1101-1107.
8. Ford ES, Ajani UA, Croft JB, Critchley JA, Labarthe DR, Kottke TE, Giles WH, Capewell S. Explaining the decrease in U.S. deaths from coronary disease, 1980-2000. N Engl J Med 2007;356:2388-2398.
9. Bandosz P, O'Flaherty M, Drygas W, Rutkowski M, Koziarek J, Wyrzykowski B, Bennett K, Zdrojewski T, Capewell S. Decline in mortality from coronary heart disease in Poland after socioeconomic transformation: modelling study. BMJ 2012;344:1-10.
10. Carroll MD, Lacher DA, Sorlie PD, Cleeman JI, Gordon DJ, Wolz M, Grundy SM, Johnson CL. Trends in serum lipids and lipoproteins of adults, 1960-2002. JAMA 2005;294:1773-1781.
11. Fox CS, Evans JC, Larson MG, Kannel WB, Levy D. Temporal trends in coronary heart disease mortality and sudden cardiac death from 1950 to 1999: the Framingham Heart Study. Circulation 2004;110:522-527.
12. Sigurdsson G, Gudnason V, Aspelund T, Siggeirsdottir K, Valtysdottir B (eds). The Icelandic Heart Association Statistical Handbook: Cardiovascular Disease in Iceland and Risk Factors. 1st ed. Reykjavik: Icelandic Heart Association; 2008.
13. Aspelund T, Gudnason V, Magnusdottir BT, Andersen K, Sigurdsson G, Thorsson B, Steingrimsdottir L, Critchley J, Bennett K, O'Flaherty M, Capewell S. Analysing the large decline in coronary heart disease mortality in the Icelandic population aged 25-74 between the years 1981 and 2006. PLoS ONE 2010;5:e13957.
14. Critchley J, Liu J, Zhao D,WeiW, Capewell S. Explaining the increase in coronary heart disease mortality in Beijing between 1984 and 1999. Circulation 2004;110: 1236-1244.
15. Palmieri L, Bennett K, Giampaoli S, Capewell S. Explaining the decrease in coronary heart disease mortality in Italy between 1980 and 2000. Am J Public Health 2010;100:684-692.
16. Bjorck L, Rosengren A, Bennett K, Lappas G, Capewell S. Modelling the decreasing coronary heart disease mortality in Sweden between 1986 and 2002. Eur Heart J 2009;30:1046-1056.
17. Mann D, Reynolds K, Smith D, Muntner P. Trends in statin use and low-density lipoprotein cholesterol levels among US adults: impact of the 2001 National Cholesterol Education Program Guidelines. Ann Pharmacother 2008;42: 1208-1215.
18. Jones PH, Davidson MH, Stein EA, Bays HE, McKenney JM, Miller E, Cain VA, Blasetto JW. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol 2003; 92:152-160.
19. Olafsdottir E, Aspelund T, Sigurdsson G, Thorsson B, Eiriksdottir G, Harris TB, Launer LJ, Benediktsson R, Gudnason V. Effects of statin medication on mortality risk associated with type 2 diabetes in older persons: the population-based AGESReykjavik Study. BMJ Open 2011;1:e000132.
20. Männistö S, Laatikainen T, Helakorpi S, Valsta LM. Monitoring diet and diet-related chronic disease risk factors in Finland. Public Health Nutrition 2010; 13:907-914.